ApolipoproteinF抗体;ApolipoproteinF Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Apolipoprotein F expression in human plasma cell lysate.    

  
  

Apolipoprotein F (ApoF), also known as β-glycoprotein I or lipid transfer inhibitor protein, is a plasma protein primarily associated with high-density lipoproteins (HDL) and low-density lipoproteins (LDL). It plays a regulatory role in lipid metabolism by inhibiting cholesteryl ester transfer protein (CETP), thereby influencing cholesterol transport and homeostasis. ApoF is implicated in cardiovascular diseases, particularly atherosclerosis, due to its interaction with lipoproteins and potential modulation of inflammatory responses.

Antibodies targeting ApoF are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies enable researchers to detect ApoF levels in serum or tissues using techniques like Western blotting, ELISA, or immunohistochemistry. They are also utilized to investigate ApoF's role in lipid metabolism disorders, metabolic syndrome, and its interplay with lipoprotein particles.

Recent studies highlight ApoF antibodies' diagnostic potential, as altered ApoF levels correlate with cardiovascular risk factors. Additionally, therapeutic applications are being explored, particularly in modulating CETP activity or addressing dyslipidemia. Monoclonal antibodies offer high specificity for mechanistic studies, while polyclonal antibodies are valuable for broad detection across experimental models. Challenges remain in standardizing assays due to ApoF's low abundance and structural complexity. Ongoing research aims to clarify its dual roles in lipid regulation and inflammation, positioning ApoF antibodies as critical reagents for advancing cardiovascular and metabolic disease research.